ENVB

NASDAQ 已收盘

Enveric Biosciences

1.35 USD
▼-0.06-4.26%
盘后 1.25 -7.41%
2026-11-20
市值
$6.04M
市盈率
—
EPS
-4.23
股息率
—
52 周区间
1.17 – 13.25
成交量
62.37K
Beta
1.21
目标价
—
52W 低 1.1752W 高 13.25
价格走势

公司简介

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary...